Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02716116 · ClinicalTrials.gov registry record · Phase 1

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

A Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Takeda.

Active
Registry status
Phase 1
Development phase
334
Enrollment target
20
Study locations

NCT02716116 is a Phase 1 study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Takeda. The registered enrollment target is 334 participants, roughly in line with the 321-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target. The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02716116, a Phase 1 study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Takeda.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
334 participants
Enrollment target
20
Study locations

Study Summary

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor decide they should stop this treatment. Participants will take TAK-788 capsules with or without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788 treatment. Non-Asian, non-White participants will take TAK-788 to determine the safety and tolerability of TAK-788 treatment.

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG TAK-788

Study Locations (20)

California

  • City of Hope Comprehensive Cancer Center - Duarte - Duarte
  • Compassionate Cancer Care - Fountain Valley - Fountain Valley
  • University of California San Diego Moores Cancer Center - La Jolla
  • Pacific Shores Medical Group-Long Beach Elm - Long Beach
  • Cancer and Blood Specialty Clinic - Los Alamitos
  • University of California Irvine Health Chao Family Comprehensive Cancer Center - Orange
  • Stanford Cancer Center - Palo Alto - Palo Alto
  • SLO Oncology and Hematology Health Center - San Luis Obispo
  • The Oncology Institute of Hope and Innovation - Whittier

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston
  • Dana Farber Cancer Institute - Boston

Arizona

  • Banner MD Anderson Cancer Center - Gilbert
  • The Oncology Institute of Hope and Innovation - West Tucson - Tucson

Alabama

  • Brookwood Medical Center - Birmingham

Colorado

  • University of Colorado Cancer Center - Aurora

Florida

  • AdventHealth Orlando - Orlando

Georgia

  • Winship Cancer Institute - Atlanta

Illinois

  • The University of Chicago Medicine - Chicago

Trial Details

FieldValue
Enrollment Target 334 participants
Start Date 2016-06-16
Est. Completion 2026-10-31
Phase Phase 1

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02716116

The ClinicalTrials.gov registry entry for NCT02716116 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 334 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 321-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which TAK-788 is the first listed.

NCT02716116 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Massachusetts, Arizona.

Frequently Asked Questions

What is clinical trial NCT02716116 about?

NCT02716116 is a clinical study titled "A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer". This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to...

What is the current status of trial NCT02716116?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 334 participants. The study started on 2016-06-16. Estimated completion is 2026-10-31.

What conditions does trial NCT02716116 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT02716116?

The interventions under investigation include: TAK-788 (DRUG).

Who is sponsoring clinical trial NCT02716116?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02716116 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.